ArticleFrontiers in oncology2025
Global, regional, and national burden of hyperglycemia-associated colorectal cancer, 1990-2021: a systemic analysis for the Global Burden of Disease study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) is a leading gastrointestinal malignancy with rising incidence. Hyperglycemia emerges as a critical driver of CRC progression, yet its global disease burden, particularly regarding health inequality and years lived with disability (YLDs), remains underexplored. Methods: This study leverages the Global Burden of Disease (GBD) 2021 dataset to analyze hyperglycemia-associated CRC burden across 21 regions and 204 countries from 1990 to 2021. It incorporates deaths, disability-adjusted life years (DALYs), YLDs, and years of life lost (YLLs), employing hierarchical clustering and health inequality metrics like the slope index of inequality and concentration index. Projections for 2022-2040 are generated using age-period-cohort models. Results: Globally, age-standardized rates (ASRs) of deaths, YLDs, YLLs, and DALYs attributed to hyperglycemia-associated CRC showed upward trends from 1990 to 2021, with YLDs exhibiting the highest consistent increase (EAPC = 1.47, 95% UI:1.35-1.60). Significant health disparities persisted across the 30 years, with higher burdens concentrated in high-socio-demographic index (SDI) regions. Notably, while mortality-related burdens slightly decreased in high-SDI areas, YLDs continued to rise, indicating unmitigated disability burdens. Projections suggest stable death rates but increasing YLDs, DALYs, and YLLs through 2040. Conclusion: Hyperglycemia-associated CRC imposes an escalating global burden, marked by persistent health inequalities and rising long-term disabilities. Urgent strategies to enhance glycemic control, expand CRC screening, and address cross-national disparities are imperative to alleviate this burden.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.